Identification of micro-RNA expression profile related to recurrence in women with ESMO low-risk endometrial cancer

Abstract

BackgroundActual European pathological classification of early-stage endometrial cancer (EC) may show insufficient accuracy to precisely stratify recurrence risk, leading to potential over or under treatment. Micro-RNAs are post-transcriptional regulators involved in carcinogenic mechanisms, with some micro-RNA patterns of expression associated with EC characteristics and prognosis. We previously demonstrated that downregulation of micro-RNA-184 was associated with lymph node involvement in low-risk EC (LREC). The aim of this study was to evaluate whether micro-RNA signature in tumor tissues from LREC women can be correlated with the occurrence of recurrences.MethodsMicroRNA expression was assessed by chip analysis and qRT-PCR in 7 formalin-fixed paraffin-embedded (FFPE) LREC primary tumors from women whose follow up showed recurrences (R+) and in 14 FFPE LREC primary tumors from women whose follow up did not show any recurrence (R−), matched for grade and age. Various statistical analyses, including enrichment analysis and a minimum p-value approach, were performed.ResultsThe expression levels of micro-RNAs-184, -497-5p, and -196b-3p were significantly lower in R+ compared to R− women. Women with a micro-RNA-184 fold change < 0.083 were more likely to show recurrence (n = 6; 66%) compared to those with a micro-RNA-184 fold change > 0.083 (n = 1; 8%), p = 0.016. Women with a micro-RNA-196 fold change < 0.56 were more likely to show recurrence (n = 5; 100%) compared to those with a micro-RNA-196 fold change > 0.56 (n = 2; 13%), p = 0.001.ConclusionsThese findings confirm the great interest of micro-RNA-184 as a prognostic tool to improve the management of LREC women.

The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis

“…However, to date, few studies have addressed its role in EC, except for a functional study by Li et al [80] demonstrating that miR-34c acts as a tumor suppressor miR in human endometrial cancer 1b (HEC-1b) with the E2F transcription factor 3 (E2F3) being one of the targets. It has also been reported that decreased expression of miR-184 is associated with recurrence in endometrial cancer [81].…”

Circular RNA DGKB Promotes the Progression of Neuroblastoma by Targeting miR-873/GLI1 Axis

“…MiRNAs are short non-coding transcripts with 22 nucleotides in length (13). Numbers of studies have demonstrated that miRNAs played significant roles in RNA translation and degradation via binding to the 3 ′ UTR of mRNA (14).…”

MicroRNA as Epigenetic Modifiers in Endometrial Cancer: A Systematic Review

“…Over the last 5 years, up to 754 miRNAs [ 17 ] have been identified as potential biomarkers in EC, some of which are correlated with lymph node involvement, advanced FIGO stage, metastatic status, or histologic type [ 17 , 40 , 103 , 118 , 161 , 162 ]. Increasing our knowledge of the miRNA expression status or the methylation state of key miRNA loci may help to better stratify patients.…”